Status:
RECRUITING
Cybersickness Prevention and Mitigation in Virtual Reality for Healthy Volunteers
Lead Sponsor:
National Human Genome Research Institute (NHGRI)
Conditions:
Healthy Volunteers
Virtual Reality
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Background: People use virtual reality (VR) technology to play games, socialize, work, or receive medical care. Some people have "cybersickness" after using VR. Cybersickness is similar to motion sic...
Detailed Description
Study Description: This study involves investigation of a virtual reality (VR) experience intended to prevent cybersickness (similar to motion sickness and eye strain) from use of virtual reality equ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Aged 18-60
- Ability to read, speak, and write in English
- Normal or corrected-to-normal hearing
- Normal vision or corrected-to-normal without use of glasses. Contact lenses for corrective purposes are acceptable.
- Ability to read, speak and write in English is a requirement because the VR-based study materials and assessment are only available in English and several of the key questionnaires for the study are not validated in other languages.
- EXCLUSION CRITERIA:
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Reporting motion sickness propensity of 0, 9 or 10 on a 0-10 scale where 0 =never experience motion sickness and 10 = experience motion sickness very frequently (self-assessed by participants).
- Reporting a history of photo-sensitive seizure disorders, vestibular disorders and/or other conditions that may make participants prone to nausea, dizziness, vertigo, ataxia, or incoordination.
- Known pregnancy
- Reporting current use of medication or supplements that inhibit nausea, e.g., Zofran/ondansetron, Phenergan/promethazine
Exclusion
Key Trial Info
Start Date :
September 26 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06552754
Start Date
September 26 2025
End Date
July 1 2026
Last Update
January 9 2026
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Iowa State University
Ames, Iowa, United States, 50011
2
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892